A new Phase 2 clinical trial involving thymosin alpha-1, known as thymalfasin, was listed as not yet recruiting as of August 21, 2026. The trial, registered as NCT07780721, is titled "Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer."
According to the registration, the study will evaluate this combination as a neoadjuvant treatment approach for esophageal cancer. The trial is registered at the Phase 2 stage. Its current status on ClinicalTrials.gov is not yet recruiting, meaning participant enrollment has not begun.
No outcome data, efficacy findings, or safety results have been reported for this trial at this stage. The registration reflects only the trial's design and current recruitment status as of the listed date. Thymosin alpha-1 remains classified as an unapproved compound under research investigation, and its use in this trial is limited to the clinical study context described.
Readers interested in ongoing developments involving thymosin alpha-1 can find more information in the compound overview for additional context.